Is PT-141 (Bremelanotide) Legal in Louisiana? How to Access It Legally
HealthRX.com
PT-141 is legal only as prescription Vyleesi, not research vials
See the public record for Bremelanotide
At a glance
- Federal status / Prescription drug, FDA-approved as Vyleesi (NDA 210557) [1][2]
- Approval date / June 21, 2019 [2]
- Approved use / Premenopausal women with acquired, generalized HSDD [1]
- Not indicated for / Postmenopausal women, men, or enhancing sexual performance [1]
- Form and dose / 1.75 mg subcutaneous autoinjector, as needed [1]
- Boxed warning / None [1]
- Prescription required / Yes; Vyleesi is prescription-only [1]
- Research-use 'PT-141' / Not Vyleesi [1][4]
Bremelanotide is a prescription drug, not a research chemical
Bremelanotide is the active ingredient in Vyleesi, an FDA-approved prescription product (NDA 210557) first approved on June 21, 2019 [1][2]. It comes as a 1.75 mg prefilled autoinjector that the patient self-injects into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity [1]. The label says not to use more than one dose within 24 hours and that more than 8 doses per month is not recommended [1].
That approval is what separates bremelanotide from peptides sold for laboratory use. A vial labelled 'PT-141, for research use only' is not Vyleesi, and it is not an FDA-approved drug [1][4].
Does Louisiana add its own rules?
FDA approval is a federal status, and Vyleesi is prescription-only [1]. Louisiana's own requirements for telehealth prescribing, prescriber eligibility and dispensing are outside what this page covers.
Questions worth asking
Compounded and 'research use' PT-141
Compounded bremelanotide sits outside that approval. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before marketing [3]. Bremelanotide does not appear on FDA's list of bulk substances that may present significant safety risks when compounded (content dated 04/22/2026), and it is not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [5][6].
Who the approved product is for
The approved indication is narrow: premenopausal women with acquired, generalized HSDD, meaning low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, relationship problems, or a medication or drug [1]. Acquired means it developed in a woman who previously had no such problem; generalized means it occurs regardless of the type of stimulation, situation or partner [1].
The label states Vyleesi is not indicated for HSDD in postmenopausal women or in men, and is not indicated to enhance sexual performance [1]. It carries no boxed warning, and no risk evaluation and mitigation strategy appears in the label or the 2019 approval letter [1][2].
What the label says to watch for
Each dose raises blood pressure briefly. In clinical studies the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with heart rate down up to 5 beats per minute; values usually returned to baseline within 12 hours [1]. In an 8-day ambulatory study of 127 premenopausal women, mean daytime blood pressure rose 1.9 mmHg systolic and 1.7 mmHg diastolic [1]. The label lists uncontrolled hypertension and known cardiovascular disease as contraindications [1].
Nausea was reported by 40.0% of patients versus 1.3% on placebo; 13% used an anti-nausea medicine and 8% stopped the trials because of it [1]. The label says pre-treating with oral ondansetron 30 minutes before a dose did not reduce nausea in a phase 4 study of 228 healthy women and is not recommended [1].
Focal hyperpigmentation (darkening of skin, gums or breasts) was reported by 1% of patients using up to 8 doses a month versus none on placebo; in another study 38% developed it after daily dosing for 8 days [1].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Is PT-141 (Bremelanotide) legal in Louisiana?
Do I need a prescription for bremelanotide?
Is compounded bremelanotide FDA-approved?
Can men get a bremelanotide prescription?
Does Vyleesi carry a boxed warning or REMS?
References
Show all 6 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration.
- Human Drug Compounding Laws | FDA.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Official web page.